Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC40H53BrFN9O13 |
InChIKeyBVQZWOPTIZSOAW-UHFFFAOYSA-N |
CAS Registry2488851-89-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 10 Oct 2020 | |
| Neoplasms | Preclinical | China | 10 Oct 2020 |





